Here's Why Arbutus (ABUS) Surged in Q3 [Yahoo! Finance]
Whitefort Capital Sends Letter to Arbutus Biopharma Board of Directors [Yahoo! Finance]
Whitefort Capital Sends Letter to Arbutus Biopharma Board of Directors
Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat
Arbutus Biopharma Co. (NASDAQ: ABUS) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $5.00 price target on the stock.